Immunology & Microenvironment
The tumour microenvironment holds great potential for therapeutic targeting.
For many solid tumours, the immune component of the tumour microenvironment (TME) offers great potential for therapeutic targeting.
We aim to develop a deep understanding of the nature of the immune TME. We also aim to determine:
- how it is regulated
- how it influences cancer growth
- how it can be manipulated to stimulate a beneficial immune response against the tumour
How we work
We use a combination of cutting-edge technologies. We interrogate the cellular and molecular makeup of the TME across a number of human cancers (e.g. liver, colorectal, pancreatic). We do this alongside the development and use of bespoke pre-clinical experimental models for mechanistic and interventional studies. These lead onto to the design of novel therapeutic approaches.
We collaborate with clinical colleagues and industry partners. Collaboration helps us to:
- carry out clinical studies/trials
- develop biomarkers that improve cancer diagnosis, prognosis and care
Our groups
Hepatocellular Carcinoma
- PIs
- Helen Reeves, Derek Mann, Caroline Wilson, Fiona Oakley, Derek Mannas
- Early Career Researchers
- ECRs are Daniel Geh, Jack Leslie and Sandra Murphy
.jpg)
.jpg)
.jpg)